1. Version 10

2. Mission; Foster adoption of… pragmatic and cost effective standards for accurate and reproducible longitudinal quantitation of biologic parameters with clinical relevance and known sigma

3. Monitoring Rx Benefit = Individualized Medicine Convergence of Biomarkers and Diagnostics H/o Commercial Dx Individuals - thresholds Categorical, staging Workflow/# studies Binary – choice of Rx Biomarkers become Dx Populations – means Continuous, quantitative Automation/bias Longitudinal – Rx effect Quantifying the effects of drugs in development may beg access to biomarkers as diagnostics

4. Milestone horizon/PET-CT Quantitation Computation Documentation of terms RSNA ‘08 RSNA ‘09 RSNA ’10 and on Feasibility H, M, L Value H, M, L Priority H, M, L Chair H, M, L High Interoperability of Results Encoding Image Quality Metrics Calibration Phantoms Characterization Lo, Hi rads RoI Definition* Dynamic Range lesion size** High Medium High Quick Hits Clunie High N/A High TBN **Ideal Phantom 2010-11 Current phantom by 2008 *Adoption 2010-11, but Define by 2008

5. Version 10